Drugs / QEQ278
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05462873 | Apr 2023 → Jan 2026 | esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma, renal cell carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QEQ278 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05462873 ↗ |
| Route | Intravenous | “Intravenous dosing of QEQ278” NCT05462873 ↗ |